544647

Nephrocare Health Services Limited reiterated its medium-term revenue CAGR guidance of 15-20% over the next 3-4 years. This growth will be fueled by expanding its network, with plans to add 40-50 new clinics annually in India and 12-15 in the Philippines. The company will maintain its focus on dialysis services, including early-stage CKD prevention, and continue investing in technology, notably rolling out its Reformmed.AI application across its network. International expansion, particularly in markets like Saudi Arabia (currently in an investment phase with the first clinic launching soon), is expected to drive higher revenue per treatment and margins. The company, which holds INR 500 crores in cash, emphasizes disciplined capital allocation. Management noted that Q4 FY26 EBITDA margins were impacted by a one-time INR 10 crore Expected Credit Loss (ECL) provision for old receivables, but affirmed that excluding this, margins would be strong.

Nephrocare Health Services Limited will attend a virtual Investor Conference hosted by Choice Broking on June 11, 2026, at 11:00 A.M. IST. Officials will engage in a group meeting where discussions will be based on publicly available information, with no unpublished price sensitive information intended to be discussed.

Nephrocare Health Services Limited announced its participation in the BOFA Healthcare Tour, an investor conference hosted by Bank of America, on June 04, 2026, in Hyderabad. The company officials will engage in group and one-on-one meetings to discuss publicly available information, ensuring no unpublished price sensitive information is shared.

Nephrocare Health Services Limited's wholly-owned Singapore subsidiary, Nephrocare Health Services International Pte. Ltd., has incorporated a new step-down wholly-owned subsidiary, NEPHROPLUS HEALTH SERVICES KAZAKHSTAN Limited Liability Partnership (LLP), in Kazakhstan on May 26, 2026. This subsidiary, with a charter capital of KZT 5,000,000 (approx. USD 10,500), aims to expand the company's kidney care and dialysis services network in Kazakhstan, including establishing and operating dialysis centers.

Nephrocare Health Services Limited announced that its officials will attend the HSBC Singapore Conference in Mumbai on June 18-19, 2026, for analyst/institutional investor meetings. Discussions will be based on publicly available information, and no unpublished price sensitive information will be shared.

Nephrocare Health Services Limited (Nephroplus) announced that its officials will be attending an Investor Conference (Non-Deal Roadshow with Group/1*1 meetings) hosted by Citi on June 15th & 16th, 2026, in Mumbai. Discussions will be based on publicly available information.

Nephrocare Health Services Limited's overseas subsidiary, Nephrocare Health Care Services Philippines Inc., has acquired assets pertaining to two dialysis centers in the Philippines: Northern Mindanao Dialysis Clinic Inc. for approximately INR 4.25 Crores and Aliaga Hemodialysis Centre Inc. for approximately INR 6.99 Crores, totaling around INR 11.24 Crores. The acquisitions are aimed at expanding the company's footprint in the Philippines.

Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) announced that its officials will attend an Investor Conference with Axis Capital on June 02, 2026, at 11:00 A.M. IST in Mumbai. The meeting will involve group and one-on-one interactions with analysts and institutional investors, with discussions limited to publicly available information.

Nephrocare Health Services Limited announced the availability of the audio recording of its Investors' Conference Call held on May 20, 2026. The call discussed the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The audio recording is accessible via a provided link and on the company's website.

The Board of Directors of Nephrocare Health Services Limited, at its meeting on May 19, 2026, approved the Audited Standalone Financial Results for Q4 FY26 and FY26. For Q4 FY26, standalone revenue grew 13.32% YoY to ₹164.33 Cr, and PAT increased 91.96% YoY to ₹10.89 Cr. Additionally, the board approved an investment of up to ₹10 Cr in its Nepal subsidiary and in-principal approval for collateral/security support of up to ₹70 Cr each for its Singapore and Saudi Arabia subsidiaries to facilitate overseas credit facilities for international expansion.

The Board of Directors of Nephrocare Health Services Limited met on May 19, 2026, and approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The company reported a standalone net loss of ₹80.60 million for FY26, a significant decline from ₹342.36 million net profit in FY25. The Board also approved an investment of up to ₹10 Crore in its Nepal subsidiary and collateral support aggregating ₹70 Crore each for its Singapore and Saudi Arabia subsidiaries to enable credit facilities. M/s. BDO India LLP was re-appointed as Internal Auditor for FY2026-27.

Consolidated Revenue ₹265.6Cr vs ₹219.2Cr (▲21.2% YoY), Adj. EBITDA ₹55.4Cr vs ₹54.0Cr (▲2.6% YoY), Adj. PAT ₹35.1Cr vs ₹27.6Cr (▲27.4% YoY). Adj. EBITDA Margin 20.9% vs 24.6% (▼380bps).